A detailed history of Harbour Investments, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Harbour Investments, Inc. holds 106 shares of BMRN stock, worth $7,062. This represents 0.0% of its overall portfolio holdings.

Number of Shares
106
Previous 100 6.0%
Holding current value
$7,062
Previous $8,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$69.02 - $93.84 $414 - $563
6 Added 6.0%
106 $7,000
Q2 2024

Jul 26, 2024

SELL
$74.43 - $92.22 $11,536 - $14,294
-155 Reduced 60.78%
100 $8,000
Q1 2024

Jul 22, 2024

BUY
$83.81 - $99.0 $921 - $1,089
11 Added 4.51%
255 $22,000
Q4 2023

Feb 16, 2024

BUY
$76.22 - $98.51 $9,756 - $12,609
128 Added 110.34%
244 $23,000
Q3 2023

Nov 15, 2023

BUY
$85.07 - $94.48 $1,871 - $2,078
22 Added 23.4%
116 $10,000
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $86 - $100
1 Added 1.08%
94 $8,000
Q1 2023

May 15, 2023

BUY
$87.74 - $117.27 $2,544 - $3,400
29 Added 45.31%
93 $9,000
Q4 2022

Feb 15, 2023

SELL
$80.93 - $108.63 $1,052 - $1,412
-13 Reduced 16.88%
64 $6,000
Q2 2022

Aug 15, 2022

SELL
$71.48 - $86.85 $3,288 - $3,995
-46 Reduced 37.4%
77 $6,000
Q4 2021

Feb 16, 2022

SELL
$71.72 - $91.47 $104,065 - $132,722
-1,451 Reduced 92.19%
123 $11,000
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $9,271 - $10,598
124 Added 8.55%
1,574 $122,000
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $302 - $339
-4 Reduced 0.28%
1,450 $121,000
Q1 2021

Aug 17, 2021

BUY
$74.73 - $90.69 $108,209 - $131,319
1,448 Added 24133.33%
1,454 $110,000
Q1 2021

May 12, 2021

BUY
$74.73 - $90.69 $448 - $544
6 New
6 $0

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.